Drugs / M28z1XXPD1DNR CAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06623396 | Sep 2024 → Sep 2028 expected | breast neoplasm, diabetes mellitus, esophageal adenocarcinoma, gastroesophageal adenocarcinoma +1 | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M28z1XXPD1DNR CAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06623396 ↗ |
| Modality | Cell therapy | “MSLN-targeted CAR T cells” NCT06623396 ↗ |
| Target | MSLN | “MSLN-targeted CAR T cells” NCT06623396 ↗ |